Menu Search
Equities

Genmab A/S

GMAB:CPH

Genmab A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)1,765.00
  • Today's Change5.50 / 0.31%
  • Shares traded72.57k
  • 1 Year change-31.85%
  • Beta1.1328
Data delayed at least 15 minutes, as of Sep 19 2024 15:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 16-Sep-24
Select bar for recommendation details.
Recommendations16-Sep-24
Buy4
Outperform11
Hold7
Sell1
Strong Sell2

Share price forecast in DKK

The 20 analysts offering 12 month price targets for Genmab A/S have a median target of 2,554.50, with a high estimate of 4,900.00 and a low estimate of 1,600.00. The median estimate represents a 45.18% increase from the last price of 1,759.50.
High178.5%4,900.00
Med45.2%2,554.50
Low-9.1%1,600.00

Earnings history & estimates in DKK

On Aug 08, 2024, Genmab A/S reported 2nd quarter 2024 earnings of 21.70 per share. This result exceeded the 20.57 consensus of the 12 analysts covering the company and exceeded last year's 2nd quarter results by 5.29%.
The next earnings announcement is expected on Nov 06, 2024.
Average growth rate+25.74%
Genmab A/S reported annual 2023 earnings of 66.02 per share on Feb 14, 2024.
Average growth rate+34.47%
More ▼

Revenue history & estimates in DKK

Genmab A/S had 2nd quarter 2024 revenues of 5.40bn. This bettered the 5.09bn consensus of the 11 analysts covering the company. This was 89.28% above the prior year's 2nd quarter results.
Average growth rate+7.64%
Genmab A/S had revenues for the full year 2023 of 16.47bn. This was 12.87% above the prior year's results.
Average growth rate+39.32%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.